Ferriere J P, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G, Plagne R
Am J Hematol. 1985 May;19(1):47-53. doi: 10.1002/ajh.2830190107.
beta-Thromboglobulin (beta TG) plasma levels were determined in 52 female breast cancer patients at different stages and in 39 healthy controls (22 women and 17 men) of similar age distribution. Beta TG levels were high (mean +/- SD:61.6 +/- 59.1 ng/ml) in patients before any treatment compared to controls (mean +/- SD:21.2 +/- 7.4 ng/ml) and the difference was statistically significant (p less than 0.001). No correlation with disease stage was observed. No other coagulation parameters were abnormal except fibrinogen, which increased. Fibrinogen degradation products (FDP) also increased but only in metastatic patients. Chemotherapy appeared to induce a considerable decrease in initial values at the end of the first cycle without modifying the platelet count. In addition, an attempt was made to correlate the beta TG plasma level investigated serially for several months with disease evolution.
对52例处于不同阶段的女性乳腺癌患者以及39名年龄分布相似的健康对照者（22名女性和17名男性）测定了β-血小板球蛋白（β-TG）的血浆水平。与对照组（均值±标准差：21.2±7.4 ng/ml）相比，未经任何治疗的患者β-TG水平较高（均值±标准差：61.6±59.1 ng/ml），差异具有统计学意义（p＜0.001）。未观察到与疾病分期相关。除纤维蛋白原增加外，无其他凝血参数异常。纤维蛋白原降解产物（FDP）也增加，但仅在转移性患者中。化疗似乎在第一个周期结束时使初始值大幅下降，而血小板计数未改变。此外，还尝试将连续数月检测的β-TG血浆水平与疾病进展相关联。
